logo
Calm Health Expands Globally, Starting with UK and Canada

Calm Health Expands Globally, Starting with UK and Canada

Business Wire2 days ago

PALO ALTO, Calif.--(BUSINESS WIRE)-- Calm, a leading mental health company, today announced the international expansion of Calm Health, its evidence-based app that provides consumers access to mental health support through their employers, health plans or providers.
Calm Health's global rollout begins in the UK and Canada, driven by growing consumer demand for accessible, scalable, and engaging mental health support. The expansion also gives multinational employers a single, unified solution extending Calm's impact across borders while streamlining support for global workforces.
The need for mental health support is urgent: globally, more than 70% of people experiencing mental health challenges don't seek help, often due to stigma, uncertainty, or limited access.
'Most employers see less than 5% engagement with their employee assistance programs. Without engagement, we can't expect meaningful outcomes,' said David Ko, CEO of Calm. 'In the U.S., Calm Health is already driving above-average engagement across employer and health plan populations, a strong signal that we're meeting a critical need as demand rises here in the U.S. and worldwide. Expanding globally is a natural next step to make mental health support more accessible.'
Calm Health provides a personalized consumer experience designed to break through barriers for those seeking mental health support. It begins with an in-app mental health screening, paired with user inputs on physical health conditions and life experiences. Based on results, users receive tailored recommendations, including in-app mindfulness and sleep content, psychologist-developed digital programs or existing employer or health plan benefits. Calm Health integrates with employer and health plan benefits ecosystems to increase visibility and engagement across the full spectrum of care.
In the U.S., Calm Health has shown measurable impact, with 77% of users completing a mental health screening, a key driver of early intervention. Calm Health members are also twice as likely to engage in outpatient mental health care when needed compared to baseline groups*. The platform has also helped increase engagement with underutilized benefits and reached underserved populations, closing critical gaps in access and care, successes that set the foundation for global expansion.
"The demand for accessible mental health resources in the UK has grown significantly, which we've seen through the strong adoption of Calm, both by individuals and employers,' said Alex Will, President at Calm. 'With Calm Health, we can now deepen our support by bringing evidence-based mental health resources to the market, designed to complement both the public health system and existing employer benefits. This expansion also allows us to better support companies with global teams by offering a single tool their people can rely on, wherever they are."
In Canada, demand for mental health support is also rising, yet many people face significant barriers to accessing care, most commonly due to cost and limited availability of services.
Calm Health is currently available to more than 17 million people in the U.S. through employers, health plans, and providers, and is built to meet the needs of diverse populations. Designed with local regulatory requirements in mind, Calm Health complies with HIPAA and HITRUST standards in the U.S. and aligns with applicable data privacy laws in the UK and Canada.
Calm Health will expand to additional international markets later this year. To explore how Calm Health can support your populations, visit health.calm.com.
*Engagement data from one of Calm's large U.S. national health plan partners. For privacy and compliance, source name is anonymized.
About Calm
Calm is a leading consumer mental health company on a mission to support everyone on every step of their mental health journey. Known for its flagship consumer app—ranked #1 in its category with over 180 million downloads and available in seven languages across around 190 countries—Calm helps people sleep better, stress less, and live more mindfully through content and tools from experts and beloved celebrity voices. Building on this foundation, Calm has created a broader portfolio including evidence-based solutions like Calm Health, offered through employers, health plans and providers, designed to expand access to mental health and sleep support, boost benefits engagement, and drive positive health outcomes. Today, Calm supports more than 3,500 organizations and reaches over 17 million covered lives through Calm Health. Calm has been recognized as a TIME100 Most Influential Company and one of Fast Company's Brands That Matter. Learn more at calm.com.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Yahoo

time2 hours ago

  • Yahoo

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES, June 04, 2025--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 2, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 18,250 shares of Puma common stock to three new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, June 1, 2025, and one-sixth of the shares underlying the award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4). About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc. In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer. View source version on Contacts Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500info@ ir@

FIGS Announces Participation in the Oppenheimer 25th Annual Consumer Growth and E-Commerce Conference
FIGS Announces Participation in the Oppenheimer 25th Annual Consumer Growth and E-Commerce Conference

Business Wire

time4 hours ago

  • Business Wire

FIGS Announces Participation in the Oppenheimer 25th Annual Consumer Growth and E-Commerce Conference

SANTA MONICA, Calif.--(BUSINESS WIRE)--FIGS, Inc. (NYSE: FIGS), the global leading healthcare apparel brand dedicated to improving the lives of healthcare professionals, today announced that Trina Spear, Chief Executive Officer and Co-Founder, and Sarah Oughtred, Chief Financial Officer, are scheduled to participate in a fireside chat at the Oppenheimer 25th Annual Consumer Growth and E-Commerce Conference on Tuesday, June 10, 2025, at 11:15 a.m. ET. The audio portion of the fireside chat will be webcast live over the internet and can be accessed at An online archive will be available on that site for a period of 90 days following the fireside chat. About FIGS FIGS is a founder-led, direct-to-consumer healthcare apparel and lifestyle brand that seeks to celebrate, empower and serve current and future generations of healthcare professionals. We create technically advanced apparel and products that feature an unmatched combination of comfort, durability, function and style. We share stories about healthcare professionals' experiences in ways that inspire them. We build meaningful connections within the healthcare community that we created. Above all, we seek to make an impact for our community, including by advocating for them and always having their backs. We serve healthcare professionals in numerous countries in North America, Europe, the Asia Pacific region and the Middle East. We also serve healthcare institutions through our TEAMS platform.

iA Financial Group Announces a $50,000 Donation to the Red Cross to Provide Emergency Aid to Wildfire Victims in Western Canada
iA Financial Group Announces a $50,000 Donation to the Red Cross to Provide Emergency Aid to Wildfire Victims in Western Canada

Business Wire

time4 hours ago

  • Business Wire

iA Financial Group Announces a $50,000 Donation to the Red Cross to Provide Emergency Aid to Wildfire Victims in Western Canada

QUEBEC CITY--(BUSINESS WIRE)--iA Financial Group is joining the Canadian Red Cross by granting a $50,000 donation to the 2025 Manitoba Wildfires Appeal​. 'We want to express our support to the communities affected by the wildfires. We are deeply saddened by the loss of lives and the damage caused by these fires, and we want to offer our support to those who need it most,' said Denis Ricard, President and Chief Executive Officer of iA Financial Group. Donations to the Canadian Red Cross will be used for assisting those impacted by the wildfires with immediate and ongoing relief including financial assistance, support to evacuees and the communities hosting them, recovery and resilience efforts in response to the wildfires, as well as supporting community preparedness and risk reduction for future all-hazard disaster events in these regions. About iA Financial Group iA Financial Group is one of the largest insurance and wealth management groups in Canada, with operations in the United States. Founded in 1892, it is one of Canada's largest public companies. It is listed on the Toronto Stock Exchange under the ticker symbol IAG (common shares). iA Financial Group is a business name and trademark of iA Financial Corporation Inc.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store